Multi-scale Mechanisms of Maxing Shigantang in Treating Pneumonia Based on Transcriptomic Data.
Chinese Journal of Experimental Traditional Medical Formulae
; 29(1):82-90, 2023.
Article
in Chinese
| EMBASE | ID: covidwho-2316540
ABSTRACT
Objective:
Pneumonia is an infectious inflammation of the alveoli,distal airway,and interstitium caused by bacterial,viral,and other pathogens. Maxing Shigantang,originated from Treatise On Cold Damage Diseases,is a classic prescription for treating pneumonia,with significant clinical efficacy. However,its treatment mechanism is still elusive. Method(s) In that paper,the transcriptome-based multi-scale network pharmacology was used to reveal the overall pharmacological mechanism of Maxing Shigantang in treating pneumonia from six scales of tissue,cell,pathological process,biological process,signaling pathway, and target. Result(s)At the tissue level,Maxing Shigantang mainly acted on the focal tissue of pneumonia-lung and the main inflammatory immune tissues-blood and spleen. Analysis of cell,pathological process and biological process suggested that Maxing Shigantang could treat pneumonia by reversing inflammatory and immune functions and improving cardiopulmonary and vascular injury caused by pneumonia. Analysis of signaling pathway and target showed that Maxing Shigantang regulated inflammatory immune response pathways such as "coronavirus disease-COVID-19" and "Toll-like receptor signaling pathway",and related targets such as "MAPKAPK3" and "NRG1". Conclusion(s)This paper,from molecular to tissue levels,indicated Maxing Shigantang treated pneumonia mainly by regulating inflammatory immune response and improving cardiopulmonary and vascular injury.Copyright © 2023, China Academy of Chinese Medical Sciences Institute of Chinese Materia Medica. All rights reserved.
immune response; Maxing Shigantang; network pharmacology; pneumonia; transcriptome; article; biological functions; blood vessel injury; cardiovascular disease; coronavirus disease 2019; human; lung parenchyma; spleen; systems pharmacology; TLR signaling; transcriptomics; biochemical marker/ec [Endogenous Compound]; Chinese medicinal formula/pd [Pharmacology]; neu differentiation factor/ec [Endogenous Compound]; toll like receptor/ec [Endogenous Compound]; transcriptome/ec [Endogenous Compound]; unclassified drug; cardiopulmonary injury; focal tissue of pneumonia lung; immune functions; inflammatory immune response pathways; inflammatory immune tissue; pathological process; maxing shigan tang/pd [Pharmacology]; mitogen activated protein kinase activated protein kinase 3/ec [Endogenous Compound]
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Language:
Chinese
Journal:
Chinese Journal of Experimental Traditional Medical Formulae
Year:
2023
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS